Thymidine

also known as deoxythymidine · dThd · TDR

Developed for: 5-nucleotidase syndrome · mitochondrial DNA depletion syndrome, myopathic form
Investigated by: Biomedical Research Networking Center (CIBER) · Columbia University · Hospital Universitario 12 de Octubre · Hospitales Universitarios Virgen del Rocío · Instituto de Salud Carlos III · Medical Research Council Mitochondrial Biology Unit
+5 more
· Muscular Dystrophy Association · National Center for Research Resources (NCRR) · Universitat Autonoma de Barcelona · University of California, San Diego · University of Seville

today NCT03639701 · Ph 1/2 NCT00004658 · Ph 2

199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT03639701	May 2017 → Dec 2026 expected	mitochondrial DNA depletion syndrome, myopathic form	Columbia University	Active not recruiting	No outcome recorded
Phase 21 trial
Phase 2	NCT00004658	Mar 1995 → ?	5-nucleotidase syndrome	National Center for Research Resources (NCRR)	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Thymidine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03639701 ↗ 1 NCT00004658 ↗
Known as	deoxythymidine	“open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors” NCT03639701 ↗
Known as	dThd	“open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors” NCT03639701 ↗
Known as	TDR	“uridine (UR) and thymidine (TDR) are added to the regimen” NCT00004658 ↗
Route	Oral	“Compounds are taken orally and divided into 3 doses daily.” NCT03639701 ↗